To assess the effect of lymph node dissection (LND), number of removed nodes (NRN), and number of positive nodes (NPN), on cancer-specific mortality (CSM) in contemporary vs historical patients with pT 2-3 N any M 0 renal cell carcinoma (RCC) treated with radical nephrectomy (RN).
Introduction
The evidence regarding the benefit of lymph node dissection (LND) at radical nephrectomy (RN) is controversial. The randomised clinical trial of Blom et al. [1] , which recruited between 1988 and 1991, showed no survival benefit of LND. However, it was underpowered and included, 389 and 383 patients in the no LND and LND arms, respectively.
Moreover, it predominantly included T 1-2 patients, 72% vs 69% respectively underwent RN without or with LND. Finally, only 28% vs 31% of total patients were staged pT 3 , in whom LN invasion risk is highest [1] .
Other series focused on even more historical patients . These reports showed benefit of LND, but also relied on small single-institution databases [2, 3] . The most Fuhrman Grade, n (%) G1/G2 
Patients and Methods

Data Source
The study cohort consisted of individuals diagnosed with RCC (International Classification of Disease for Oncology C64.9) within the Surveillance, Epidemiology, and End Results (SEER) database. The SEER collects patient demographics and publishes cancer incidence and survival data from several cancer registries. The SEER database covers 26% of the USA population [6] .
Study Population
Only 
Statistical Analysis
Descriptive statistics included frequencies and proportions for categorical variables. Means, medians, and ranges were reported for continuously coded variables. The chi-square tested the statistical significance in proportions differences. The t-test examined the statistically significance in means differences.
To reduce the effect of selection bias, we used a propensity score adjustment that relied on weighting based on inverse probability of treatment (IPTW) [7] . In the first step of the analyses, we evaluated changes in LND rates over time.
Temporal trends were quantified using the annual percentage change with least squares linear regression. Then, we evaluated the effect of LND on CSM. In the second step, we examined the effect of the number of removed nodes (NRN) on CSM in patients who underwent LND. The population was stratified according to the median NRN. In the third step, we tested the effect of the NPN on CSM in patients with documented LN invasion. The population was stratified according to the median NPN. In all analyses, Kaplan-Meier plots graphically depicted the CSM-free survival rates. Univariable and multivariable Cox regression models tested for differences in CSM. All analyses were repeated according to T-stage (pT 2 and pT 3 ) in the subgroup of patients with ccRCC. All the analyses were adjusted according to historical and contemporary year of diagnosis intervals.
All tests were two-sided and a level of statistical significance was set at P < 0.05. Analyses were performed using the R software environment for statistical computing and graphics (version 3.3.0; http://www.r-project.org/).
Results
The entire study cohort consisted of 25 357 patients. In the first step of our analyses, we tested the effect of LND on CSM according to pathological T-stage: pT 2 and pT 3 . In Kaplan-Meier analyses LND did not have a protective effect on CSM, both in the pT 2 and pT 3 patients. Specifically, in the pT 2 patients the 5-year CSM-free survival according to absence or presence of LND was, respectively, 89.1% vs 83.8%. In the pT 3 patients, the 5-year CSM-free survival according to absence or presence of LND was, respectively, 80.9% vs 65.1% (P < 0.001; Fig. 1 ). In the entire cohort of pT 2 and pT 3 patients, multivariable propensity score adjusted Cox regression models showed that LND did not exhibit a protective effect on CSM (hazard ratio [HR] 1.29, 95% CI 1.21-1.36; P < 0.001). Instead, LND showed an increased risk of CSM, in both pT 2 (HR 1.13, 95% CI 1.01-1.25; P = 0.03) and pT 3 (HR 1.31, 95% CI 1.22-1.40; P < 0.001) patients (Table 2 ). All the analyses were repeated in patients with ccRCC and yielded virtually the same results. Moreover, contemporary patients exhibited a lower risk of CSM (HR 0.77, 95% CI 0.72-0.83; P < 0.001).
In the second step of our analyses, we tested the effect of the median NRN on CSM according to pathological T-stage: pT 2 and pT 3 . In Kaplan-Meier analyses, the NRN had no effect on CSM. Specifically, in pT 2 patients the 5-year CSM-free survival was 83.7% vs 83.8% (P = 0.3) in respectively, patients with NRN below vs above the median. In pT 3 patients, the 5-year CSM-free survival was 65.7% vs 64.6% (P = 0.4) in respectively, patients with NRN below vs above the median (Fig. 2) . In the entire cohort of pT 2 and pT 3 patients, multivariable propensity score adjusted Cox regression models showed that the NRN did not have an effect on CSM (HR 0.94, 95% CI 0.85-1.04; P = 0.3). The NRN was not associated with a lower risk of CSM, in both pT 2 (HR 0.82, 95% CI 0.66-1.01; P = 0.06) and pT 3 (HR 0.98, 95% CI 0.87-1.09; P = 0.7) patients (Table 3 ). All the analyses were repeated in patients with ccRCC and yielded virtually the same results. Moreover, contemporary patients exhibited a lower risk of CSM (HR 0.78, 95% CI 0.70-0.88; P < 0.001).
In the third step of our analyses, we tested the effect of the median NPN on CSM according to pathological T-stage: pT 2 and pT 3 . Kaplan-Meier analyses showed no CSM differences according to the NPN in pT 2 patients (5-year CSM-free survival rate 46.8% vs 46.2%, in respectively, patients with the NPN below vs above the median, P = 0.87). Whilst in pT 3 patients the 5-year CSM-free survival rate was 37.7% vs 28.7% in respectively, patients with the NPN below vs above the median (P = 0.02; Fig. 3 ). In the entire cohort of pT 2 and pT 3 patients, multivariable Cox regression models showed that the NPN increases CSM (HR 1.32, 95% CI 1.08-1.61; P = 0.007). Contemporary patients exhibited the same rate of CSM (HR 0.91, 95% CI 0.75-1.09; P = 0.3). The NPN effect on CSM in pT 2 subgroup analyses was not confirmed (HR 1.58, 95% CI 0.91-2.74; P = 0.1). However, worse survival with a higher NPN was confirmed in pT 3 patients (HR 1.29, 95% CI 1.03-1.60; P = 0.02) ( Table 4 ). All the analyses were repeated in patients with ccRCC and yielded virtually the same results.
Interestingly, the NRN exerted a protective effect on CSM in the entire cohort of pT 2-3 patients with positive nodes (HR 0.98, 95% CI 0.96-0.99; P = 0.007), as well as in separate subgroup analyses of pT 2 (HR 0.94, 95% CI 0.89-0.99; P = 0.02) and pT 3 (HR 0.98, 95% CI 0.96-0.99; P = 0.04). However, the NRN failed to achieve statistical significance in patients with clear cell histology in the entire cohort (HR 0.99, 95% CI 0.96-1.02; P = 0.5), as well as in the pT 2 (HR 0.94, 95% CI 0.87-1.01; P = 0.1) and pT 3 (HR 0.99, 95% CI 0.97-1.02; P = 0.9) subgroup analyses.
Discussion
The one and only randomised clinical trial examining the effect of LND on cancer survival outcomes at RN failed to show any benefit of the procedure [1] . However, that trial was underpowered, relied on very small patient numbers per participating institution, enrolled historical patients (1988-1991), and included pT 1 patients in whom LN invasion rates are so low that the benefit of LND is difficult to conceptualise. It is also noteworthy, that the proportions of patients with pT 3 disease in whom LND may be more Other non-randomised studies relied on equally historical or even more historical patients. Some reported a survival benefit [2, 3, 8] , but others did not [4, 5, [9] [10] [11] . Of contemporary studies, the Mayo Clinic reported on a large RN cohort: 1 797 patients of whom 606 underwent a LND. Here, no survival benefit was associated with LND at RN [4] . Conversely, Whitson et al. [8] showed a CSM benefit, when more extensive LND was performed in patients with positive nodes at RN or partial nephrectomy. However, this report was challenged by Sun et al. [9] , who questioned the methodological flaws that might have been introduced with missing data imputation. Also, the recent secondary analysis of the Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma (ASSURE) trial (2006) (2007) (2008) (2009) (2010) , N = 1 942), despite their prospective data source, failed to report a survival benefit of LND [12] . It could be hypothesised that there is a role of LND in patients with high-risk nonmetastatic RCC who are candidates for adjuvant systemic therapy based on the presence of LN metastases, in addition to other risk factors.
Consequently, it may be postulated that large-scale contemporary analyses of the effect of LND on CSM are warranted to corroborate or refute the benefit of LND on CSM. Ideally, such analyses should focus on the potential benefit of LND vs no LND, on the effect of the NRN, and on the relationship between the NPN and NRN in patients with positive nodes, using the most methodologically comprehensive analyses. Our present study fulfilled those criteria and showed important findings that are not going to be addressed by ongoing or even planned randomised trials, as no such trial is ongoing or planned. Based on this consideration, we hypothesised that LND, NRN and NPN may have an effect on CSM. To test our hypotheses, we performed three analytic steps.
First, we tested temporal trends of LND rates at RN and examined if LND improves CSM-free survival. Here, we found a significant decrease in LND rates in pT 2 patients, but no differences over time were found in pT 3 patients. Our present results corroborate those of Kates et al. [13] that relied on a more historic SEER database version (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) , where the authors found a significant decrease in LND rates for localised RCC. We also found that LND does not improve CSM-free survival. These observations applied to all pT 2 and pT 3 patients. Moreover, they applied to all histological subtypes, as well as to patients with exclusive ccRCC.
Our present results corroborate the findings of Joslyn et al. [5] that were based on an historical version of the SEER database (1983-1998). The authors observed an inverse relationship between cancer-specific survival and the NRN. However, their study did not only include patients with nonmetastatic RCC, but allowed inclusion of patients with distant metastases. In a more recent analysis, by Feuerstein et al. [11] that focused on 524 patients with non-metastatic RCC, with tumours ≥7 cm, the authors observed that LND and its extension were unrelated to recurrence-free or overall survival. Finally, in the most recent analysis that relied on an institutional database, Gershman et al. [4] also observed that LND did not improve CSM-and all-cause mortality-free survival across all stages, as well as in patients with increased risk of LN metastases. Conversely, Capitanio et al. [2, 3, 14] showed improved cancer-specific survival after LND in patients with localised, locally advanced or metastatic RCC.
Second, we tested if the NRN, as an indicator of LND extent, may have a protective effect on CSM. Our present results show that the NRN has no effect on CSM. Our findings corroborate those of several other authors. For example, Sun et al. [9] , relied on the historic version of the SEER database , and observed no survival benefit according LND extent at nephrectomy. Taken together our present findings, as well as those of several other investigators, show no benefit of LND at RN on CSM or other related cancer control outcomes in patients with non-metastatic RCC. Nonetheless, our present data also indicate that as many as 20% and 30% of respectively, pT 2 and pT 3 patients undergo LND at RN. Such practice might still be justified for prognostic purposes and its extent might improve its diagnostic ability [15] . In fact, the prognostic value associated with the presence of LN metastases is well recognised in the literature [16] [17] [18] [19] .
Third, we tested the role of the NPN on CSM. We found an increase in CSM that was proportional to the NPN. These findings applied to all patients and to patients with ccRCC. In stratified analyses, statistical significance was only confirmed in the pT 3 but not in pT 2 subgroup. It is of interest that the extent of LND exerted a protective effect on CSM in all patients, but not in those with clear cell histology. Our present findings regarding the NPN corroborate those of Capitanio et al. [3] . They relied on an institutional database and found a correlation between the NPN and CSM. Our present findings regarding the effect of the NRN in LN-positive patients partially agree with Whitson et al. [8] , who also showed a protective effect in pT [1] [2] [3] [4] patients, regardless of histological subtype, using missing data imputation. This approach to missing data was challenged by Sun et al. [9] , who failed to demonstrate the protective effect of LND extent in their analysis. We did not use imputation, but performed subgroup analyses in clear cell histology patients. Moreover, our present analyses focus on more contemporary patients namely The present study is not devoid of limitations. Most importantly, as in previously reported analyses that relied on prospective and retrospective databases and examined the effect of LND on RCC mortality, the extent and LND technique were not standardised. Consequently, no standardised template could be used to define the LND boundaries. Therefore, in the present study important variability exists in the NRN, across pathological stages and according to the presence or absence of LN metastases. Additionally, the specific indication for LND is not known. We have no data that could explain why a large proportion of patients underwent LND and why an even larger proportion did not. As in previous prospective and retrospective analyses, the decision to perform LND was delegated to the discretion of the operating surgeons. Moreover, we have no data about clinical N-stage in patients with available pathological N-stage. Similarly, pathological Nstage is unavailable in patients with clinical N-stage in whom LND was not performed. Consequently, the ability of clinical N-stage to predict pathological N-stage could not be examined. Similarly, we have no data on intraoperative LN appearance. However, available analyses that compared imaging clinical staging to pathological staging indicate limited ability to predict that outcome [20] . Nonetheless, several multivariable models are capable of predicting the presence of LN metastases [2, [21] [22] [23] . Furthermore, the population-based nature of the present cohort precludes a standardised pathological assessment and tissue processing. Accordingly, not all removed LNs might have been examined or analysed with the same detail, according to strict institutional protocols or preferences. Actually, to date only one group of investigators examined the rate of pathological N 1 stage in clinical N 0 , high-risk patients, within a prospective dataset with central pathology review (ASSURE trial). In a secondary analysis of that trial, the rate of occult metastases was 1.98%. However, as in all previous analyses there was no predefined LND template [12] . Last but not least, limitations related to the retrospective nature of the SEER database and lack of potentially important variables also need to be acknowledged.
In conclusion, in contemporary and historical patients, LND or its extent do not protect from CSM. However, the NPN increases the rate of CSM in pT 3 patients. Thus, LND and its extent appear to have little if any therapeutic value in pT 2- 
